FOXM1 and systemic lupus erythematosus: The resulting elevated expression of FOXM1 and its regulated genes in plasmablasts in SLE may be the result of type I IFN exposure; hence, targeting this axis may be a novel strategy for the treatment of SLE (Figure 6).